[Polymorphism and clinical significance of human paraoxonase enzyme].
The human serum paraoxonase (PON) in one of the enzymes showing pharmacogenetic polymorphism. According to our present knowledge the enzyme inhibits the lipidperoxydation and through its effect on the lipid metabolism or another pathogenetic mechanism may take part in the pathogenesis of diabetes mellitus and ishaemic heart disease.
Renczes
G
G
Haynal Imre Egészségtudományi Egyetem, I. Belgyógyászati Klinika, Budapest.
Róna
K
K
Szabó
I
I
Somogyi
A
A
D000328:Adult; D043303:Aryldialkylphosphatase; D002648:Child; D003920:Diabetes Mellitus / Q000201:enzymology*; D004950:Esterases / Q000097:blood*; D006801:Humans; D015227:Lipid Peroxidation; D008074:Lipoproteins / Q000378:metabolism; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000201:enzymology*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D008074:Lipoproteins; D004950:Esterases; D043303:Aryldialkylphosphatase